Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9215279 | 0.92 | AGTR2 (0.59) | AGTR2AGTR1 | |
| SCHEMBL8562299 | 0.90 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL708 | 0.86 | AGTR1 (0.80) | AGTR2AGTR1 | |
| SCHEMBL8843640 | 0.86 | AGTR2 (0.61) | AGTR2AGTR1 | |
| SCHEMBL9468705 | 0.85 | AGTR1 (0.78) | AGTR2AGTR1 | |
| SCHEMBL8567814 | 0.85 | GP6 (0.65) | AGTR2AGTR1 | |
| SCHEMBL8565506 | 0.84 | AGTR2 (0.69) | AGTR2AGTR1 | |
| SCHEMBL7018111 | 0.81 | AGTR2 (0.66) | AGTR2AGTR1 | |
| SCHEMBL12754340 | 0.81 | AGTR2 (0.68) | AGTR2AGTR1 | |
| SCHEMBL9483479 | 0.80 | AGTR2 (0.76) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994001436-A1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | THE BOOTS COMPANY PLC (GB) | 1994-01-20 | — | — | WO | claimed |
| EP-0649424-B1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | KNOLL AG (DE) | 1998-10-07 | — | — | EP | disclosed |
| US-5627191-A | Therapeutic agents | THE BOOTS COMPANY PLC (GB) | 1997-05-06 | — | — | US | disclosed |
| EP-0649424-A1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | Knoll AG (DE) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994001436-A1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | THE BOOTS COMPANY PLC (GB) | 1994-01-20 | — | — | WO | disclosed |